RLD and Comparator Sourcing from Europe: A Practical Guide for Clinical Trials and Generic Development

When a pharmaceutical sponsor, CRO, CDMO or generic developer needs to source a Reference Listed Drug (RLD), reference medicinal product or clinical trial comparator from Europe, the terminology alone can slow the process down. Buyers search for EU RLD sourcing and RLD sourcing Europe because that is the language the sourcing industry has settled on commercially, but neither phrase is the formal EU regulatory term, and getting the terminology wrong in a study protocol or regulatory submission has real consequences.

This guide sets out what these terms actually mean in each jurisdiction, why and when European sourcing makes sense, and the practical, operational detail that determines whether a sourcing project runs smoothly or stalls.

It is written from the sourcing side, not the regulatory affairs side. It does not give regulatory advice, and it does not claim that a European source is automatically acceptable for any given submission or study. What it does set out clearly is the terminology, the operational questions worth asking before a sourcing request goes out, and where European sourcing genuinely fits.

RLD, reference medicinal product and comparator — what do these terms actually mean?

RLD, reference medicinal product, reference product, comparator and originator get used interchangeably in day-to-day sourcing conversations. They are not interchangeable in regulatory terms. Each jurisdiction has its own formally defined language, and the definitions below are drawn from primary regulatory sources rather than sourcing industry marketing.

US/FDA — Reference Listed Drug (RLD)

In the United States, a Reference Listed Drug is a specific regulatory designation under the FDA's ANDA (Abbreviated New Drug Application) framework, codified at 21 CFR 314.3(b). FDA's Orange Book Preface describes an RLD as the listed drug FDA has identified as the drug product an applicant relies on when seeking ANDA approval. FDA guidance on referencing approved drug products in ANDA submissions confirms the same point: RLD is a US-specific concept, tied to the Orange Book and the Hatch-Waxman ANDA pathway. It does not exist as a formal designation outside the US regulatory system.

EU — reference medicinal product

The equivalent EU concept is the reference medicinal product, defined in Article 10(2)(a) of Directive 2001/83/EC as a medicinal product authorised under Article 6 in accordance with Article 8. Under Article 10(1), a generic applicant can rely on a reference medicinal product's data once it has been authorised in the EU/EEA for at least eight years, subject to further market-protection periods. EMA's own guidance on generic and hybrid medicines uses “reference medicine” or “reference product” throughout — not RLD, and not originator as a defined term.

UK — reference medicinal product vs comparator product

Post-Brexit, the UK retains its own regulatory language. Regulation 48(2) of the Human Medicines Regulations 2012 defines a Reference Medicinal Product (RMP) — the legally authorised product a generic must be shown to be equivalent to. Separately, MHRA guidance on comparator products in bioequivalence/therapeutic equivalence studies defines a Comparator Product (CP) as the actual physical product used in the study. It must be representative of the UK RMP but does not need to be identical to it, and can be sourced from outside the UK provided representativeness is demonstrated. This RMP/CP distinction maps directly onto sourcing: the CP is what you are physically procuring; the RMP is the legal benchmark it needs to represent.

Australia/TGA — Australian reference product / overseas reference product

The TGA's consultation paper on generic medicine market authorisation reform uses the term reference product, qualified as either an Australian reference product (the existing medicine approved in Australia) or an overseas reference product (a comparable medicine approved elsewhere, usable where the applicant demonstrates it is identical to the Australian reference product). TGA does not use RLD, reference medicinal product or comparator product.

Is “EU RLD” a real regulatory term? No. “EU RLD” does not appear in any EMA, European Commission or EU member state regulatory document we have identified. It is a commercial and search term, used across the sourcing and clinical supply industry because RLD is a familiar, high-recognition acronym for buyers who work across US and EU frameworks — not a phrase grounded in EU legislation. The formally correct EU term is reference medicinal product. We use “EU RLD” in places in this guide because it is the phrase buyers search for and recognise, but the distinction matters if you are relying on this content for a regulatory submission or study protocol. Always confirm terminology against the regulation that applies to your submission, not against sourcing-industry language.

Term	Jurisdiction	Official source	Practical meaning
Reference Listed Drug (RLD)	United States (FDA)	21 CFR 314.3(b); FDA Orange Book Preface	The specific drug product FDA has identified as the basis for an ANDA
Reference medicinal product	European Union (EMA/EC)	Directive 2001/83/EC, Article 10(2)(a)	The EU-authorised product a generic or hybrid application relies on
Reference Medicinal Product (RMP) / Comparator Product (CP)	United Kingdom (MHRA)	Human Medicines Regulations 2012, Reg 48(2); MHRA comparator products guidance	RMP is the legal benchmark; CP is the physical product sourced and used in the study
Reference product (Australian / overseas)	Australia (TGA)	TGA generic medicine market authorisation consultation paper	Australian reference product is TGA-approved; overseas reference product is approved elsewhere, usable if shown identical
Comparator (as an Investigational Medicinal Product)	EU clinical trials	Regulation (EU) 536/2014; European Commission Q&A, Question 1.15	A product used as a reference, including a placebo, in a clinical trial — treated as an IMP

Why source RLDs and comparators from Europe

Europe is one of several regions sponsors and generic developers source RLDs, reference medicinal products and comparators from, alongside the US, UK and other markets. It is not automatically the cheapest or fastest option, and the right sourcing market depends on what your regulatory strategy and study design actually require. Europe is worth considering when:

• your regulatory strategy specifically calls for a reference medicinal product authorised in the EU/EEA — for an EU marketing authorisation application, or where a protocol specifies an EU-sourced comparator

• you need country-specific packs, presentations or strengths that are only marketed in certain EU member states

• a product is more readily available, or available with better remaining shelf life, through EU-licensed wholesalers than through your usual market

• you need sourcing through the EU's Good Distribution Practice (GDP)-regulated wholesale network, which provides a defined, auditable framework for licensed supply

• you need a second or alternative source because a product has been discontinued, is on shortage, or is otherwise difficult to obtain in your primary target market

• 
  

None of this makes European sourcing inherently superior. A product may be more readily available, less expensive, or have a longer remaining shelf life in the US, UK or another market for a given project. The right answer depends on the specific product, the study or submission requirements, and current market availability at the time of the request.

Sourcing from Germany

Germany has a large and well-established pharmaceutical wholesale market, with an extensive network of GDP-licensed wholesalers and distributors. This makes Germany an important sourcing market when a specific product, pack, strength, batch or remaining shelf life is required. ProPG maintains pharmaceutical operations in Hamburg, supporting sourcing and distribution activity within Germany and the broader EU market.

Sourcing from Poland

Poland is a similarly significant pharmaceutical distribution market within the EU, and is well positioned logistically for onward distribution across both Western and Central/Eastern Europe. ProPG's Warsaw operation, run through its EU affiliate Jemstar, provides EU warehousing and GDP-compliant fulfilment, supporting sourcing and distribution activity into and out of the Polish and wider EU market.

What an authorised pharmaceutical supply chain actually means

Provenance is not a compliance formality — it is what makes a sourced product usable for its intended purpose, whether that is a clinical trial, a bioequivalence study or a regulatory submission. An authorised pharmaceutical supply chain means the product has moved from manufacturer to buyer only through parties holding the relevant wholesale distribution authorisation, or equivalent licence, in their jurisdiction, with each step documented. In practice, that covers a few distinct things worth understanding separately:

• Licensed wholesalers and suppliers: in the EU, GDP requires wholesale distributors to hold a wholesale distribution authorisation and to source from, and supply to, only other authorised parties. This licensing framework is what “authorised supply chain” actually refers to.

• Supply-chain traceability: the ability to show, step by step, how a specific unit or batch moved from manufacturer to end recipient, so a buyer can confirm a product is genuine and has been handled correctly throughout.

• Market of supply and country-of-manufacture verification: confirming which market a specific unit's pack and labelling were prepared for (its market presentation) and, separately, where the product was actually manufactured, where this can be established from supply-chain documentation. Regulatory submissions may have requirements relating to one, the other, or both, and the two should not be assumed to be the same thing.

• Invoice and source documentation: commercial invoices and supporting paperwork that evidence the chain of purchase from an authorised source, rather than relying on assurance alone.

• Avoiding grey-market or unverifiable supply: sourcing outside the authorised wholesale network carries real risks — inconsistent documentation and uncertain storage history — that can make a product unfit for a regulated use case such as a bioequivalence study, regardless of the supplier's intentions.

• 
  

None of this is unique to any one supplier — it reflects how GDP-regulated pharmaceutical distribution is generally required to operate in the EU and other regulated markets. What varies between suppliers is how clearly this is documented and how easily it can be provided when it is needed, which is why documentation requirements are worth confirming before, not after, a sourcing request is placed.

RLD and comparator sourcing for bioequivalence studies

Sourcing for a bioequivalence (BE) study carries a different risk profile to sourcing a comparator for a broader clinical trial, because the study result depends on the reference product being an accurate, representative sample of the approved product. A handful of details make the difference between a straightforward sourcing request and a delayed one:

• Exact strength and dosage form: the sourced product must match the strength, dosage form and, in most cases, the specific presentation your protocol or regulatory strategy specifies.

• Market of supply and country-of-manufacture restrictions from your regulatory strategy: some study designs and submission pathways require the reference product to be sourced from a specific market, and may separately require confirmation of the country the product was manufactured in. Confirm which of these applies with your regulatory team before a sourcing request is placed, not after.

• Pack size and quantity required: confirming both the pack size available and the total quantity needed — including any allowance for retesting or repeat analysis — up front avoids a second sourcing round mid-study.

• Remaining shelf life: the product needs sufficient remaining shelf life to cover the full study period, including dosing, retention samples and analytical work — checked against your study timeline, not assumed.

• Batch/lot requirements: some study designs call for product from a single batch; others can accommodate multiple batches. This should be defined as part of your study design, not resolved during sourcing.

• Stability and storage requirements: confirming storage conditions, including any cold-chain requirement, before sourcing, so the product is transported and stored correctly from the point of collection.

• Timing relative to the planned study: sourcing lead times vary by product, market and batch availability, and should be built into the study timeline rather than treated as a fixed, short window.

  
  

On single-lot sourcing specifically: ProPG can support single-lot or single-batch sourcing requirements where sufficient stock is available from an authorised source. Availability of a single lot in the quantity required cannot be guaranteed before it has been confirmed with the supply chain, and this should always be checked at quotation stage rather than assumed. Single-lot sourcing can matter operationally and for study consistency, since product from a single batch removes batch-to-batch variability as a factor. Whether single-lot sourcing is required, preferred, or unnecessary for a given study depends on the applicable regulatory guidance and your study design, and should be confirmed with your regulatory and clinical team rather than assumed to be mandatory.

What happens if the RLD or reference product is discontinued or difficult to source

Products get discontinued, withdrawn from specific markets, or become genuinely difficult to source — one of the most common practical issues generic developers and study teams run into. There is no single fix, but a few avenues are worth exploring:

• Alternative countries or markets: a product discontinued or unavailable in one market may still be commercially available, in date, and sourceable through an authorised supply chain in another.

• Checking current commercial availability: availability status changes, and a product reported as discontinued by one source may still be manufactured and supplied elsewhere, or may have been reformulated or relaunched under a new presentation.

• Assessing equivalent pack or market requirements: where a specific pack, strength or market-authorised version is unavailable, check with your regulatory team whether an equivalent presentation from another authorised market meets your requirements.

• Working within your regulatory strategy: any decision to substitute, adapt, or change the sourcing market for a reference product should be made by your regulatory and clinical team, based on the guidance applicable to your submission or study.

  
  

We are not able to advise on whether a substitute product, market or presentation is regulatorily acceptable for a specific study or submission — that assessment sits with your own regulatory affairs and clinical teams. Our role in this situation is to help establish, as quickly as possible, what is and is not currently available and where, so your team can make that decision with accurate information.

Practical pre-quote checklist

The fastest way to get an accurate quote and lead time for RLD or comparator sourcing is to have the following confirmed before you submit a request. This is the checklist ProPG's own sourcing team works through on every enquiry:

#	Confirm before you request a quote
1	Product name
2	Active ingredient
3	Strength
4	Dosage form
5	Required pack size
6	Required market of supply and/or country of manufacture (specify which)
7	Quantity required
8	Single-lot/single-batch requirement (yes/no, and why)
9	Minimum remaining shelf life
10	Storage conditions / cold-chain requirements
11	Required documentation
12	Controlled/scheduled product status
13	Required delivery destination
14	Required delivery date

Documentation to clarify before sourcing

Documentation availability varies by manufacturer, market and supply route. Confirming what is available for a specific product at quotation stage avoids assumptions that cause delays later:

Document	What it can confirm	Availability considerations
Supply-chain pedigree / source traceability	The chain of custody from manufacturer or authorised source to point of supply	Depth of traceability documentation varies by manufacturer and market — confirm at quotation stage
Commercial invoice / source documentation	Purchase through an authorised source	Standard for most authorised-supply-chain transactions; retained as part of the sourcing record
Certificate of Conformity (CoC), where applicable	The product conforms to the relevant specification	Not issued for every product or market; confirm applicability at quotation stage
Certificate of Origin (CoO), where applicable	The country in which the product was manufactured, as distinct from the market the product is authorised, packed or supplied for	Availability depends on the manufacturer and supply route
Certificate of Analysis (CoA), where available	Batch-specific analytical results such as identity, purity and assay	CoA availability depends on the manufacturer, market and supply route, and is not available for every product or batch — always confirm at quotation stage rather than assuming it will be provided
Batch/lot information	The specific batch(es) supplied	Generally available from the supplied product and/or associated shipment documentation; specific documentary requirements should be confirmed at quotation stage.
Temperature-monitoring records, for relevant shipments	Cold-chain integrity was maintained during transport	Provided for shipments using temperature-controlled transport; confirm requirement for the specific shipment
Import/export permits, for controlled products where applicable	The shipment is authorised for cross-border movement of a controlled or scheduled substance	Required only for controlled/scheduled products; lead time and requirements assessed case by case

Controlled and scheduled products

Controlled and scheduled products can involve requirements that do not apply to standard sourcing requests — import and export permits, jurisdiction-specific controls such as narcotics quota systems in some EU member states, and typically longer lead times to allow for the necessary approvals. Requirements vary by product, by the exporting and importing jurisdictions, and by the specific controlled or scheduled classification involved, so they cannot be generalised.

ProPG assesses controlled and scheduled product requests on a case-by-case basis, taking into account the specific product, the markets involved, and the documentation and permits required. If your sourcing request involves a controlled or scheduled substance, flag this at the outset so it can be assessed properly rather than partway through a standard sourcing timeline.

Cold-chain and temperature-sensitive comparator sourcing

Temperature-sensitive products need their storage and transport requirements confirmed before sourcing begins, not after a quote has been issued — including the required storage temperature range and any validated or qualified transport arrangements the product needs. Where a validated cold-chain solution is required, this should be arranged and confirmed as part of the sourcing process, with temperature monitored and recorded for the duration of transport.

Temperature excursions matter differently for a reference or comparator product than for routine stock. Where a product is being used as a reference or comparator product in an analytical or bioequivalence context, an excursion is not simply a general quality concern — it can raise a genuine question about whether the product is still suitable for its intended reference use, independent of whether it otherwise remains within its labelled shelf life. For this reason, price alone is not a sufficient basis for choosing a cold-chain sourcing option for a temperature-sensitive reference or comparator product — the validated transport arrangement and monitoring record matter as much as the landed cost.

Who this guide is for

This guide is written for the teams who commission and manage RLD, reference medicinal product and comparator sourcing directly, including:

• pharmaceutical sponsors

• CROs (contract research organisations)

• CDMOs (contract development and manufacturing organisations)

• generic manufacturers

• biosimilar developers

• bioequivalence-study teams

• clinical-trial supply teams

  
  

How ProPG supports European RLD and comparator sourcing

ProPG supports RLD, reference medicinal product and comparator sourcing across Australian and European markets. Specifically, ProPG:

• sources from Australian and European markets, with pharmaceutical operations in Melbourne, Hamburg and Warsaw, including ProPG's EU affiliate Jemstar in Poland, working through licensed pharmaceutical infrastructure and supply relationships across these markets

• works through pharmaceutical infrastructure and licensed supply relationships across these markets

• supports GDP-aligned sourcing and cold-chain supply

• works with CROs, CDMOs, pharmaceutical sponsors and generic manufacturers

• supports sourcing of hard-to-source medicines and biologics

• can support single-lot sourcing requirements where availability from an authorised source permits

• can provide supply-chain traceability and source documentation depending on the specific product and market — availability should be confirmed at quotation stage

Where a sourcing request requires relabelling, QP (Qualified Person) release, or other GMP-regulated activity, ProPG can support this through qualified European partners where applicable. This is arranged on a case-by-case basis for the specific product and market, rather than performed as a standard in-house service.

If you have an RLD, reference medicinal product or comparator sourcing requirement, the fastest way to get an accurate quote is to work through the checklist above and speak to our Comparator and RLD Sourcing team, or contact us directly. You can also read more about our European sourcing footprint.

Frequently asked questions

Is “EU RLD” an official regulatory term?

No. RLD is a US FDA term defined under 21 CFR 314.3(b) and the FDA Orange Book. The EU's own term for the equivalent concept is reference medicinal product, defined in Directive 2001/83/EC, Article 10(2)(a). “EU RLD” is a commercial and search phrase used across the sourcing industry, not a term found in EU legislation or EMA guidance.

What is the difference between an RLD and a reference medicinal product?

They describe broadly equivalent concepts in different jurisdictions rather than the same thing. RLD is the FDA's designation for the specific drug product an ANDA applicant relies on. Reference medicinal product is the EU's equivalent term, defined under Directive 2001/83/EC, for the EU-authorised product a generic or hybrid application relies on. The two are not formally interchangeable, and which one is relevant depends on which jurisdiction's application or study you are working to.

What is the difference between a reference medicinal product and a comparator?

A reference medicinal product is the legally authorised product a generic or hybrid application is assessed against. A comparator, particularly in UK/MHRA and EU clinical-trial terminology, is generally the actual physical product used in a study — it must be representative of the reference medicinal product but does not always need to be identical to it. In practice, a comparator is what you are sourcing and using; a reference medicinal product is the regulatory benchmark it needs to represent.

Can a European-sourced reference product be used for an FDA, EMA or TGA submission?

This depends entirely on the specific regulatory pathway and guidance applicable to your submission, and is a question for your own regulatory affairs team rather than something we can answer generally. We can help establish what is currently available and from which market; whether a specific sourced product meets the requirements of a specific submission is a regulatory determination, not a sourcing one.

Why does country of origin matter?

This depends on which sense of “origin” your submission cares about, since the two are not the same thing. Some submissions or protocols require the reference product to be sourced from, or shown to be identical to, a product authorised in a specific market — a question of market of supply or pack presentation. Others require confirmation of the country the product was actually manufactured in, which is a separate question established through supply-chain documentation such as a Certificate of Origin. Confirm with your regulatory team which of these your submission actually requires, rather than assuming they are interchangeable.

Can ProPG support single-lot sourcing?

ProPG can support single-lot or single-batch sourcing requirements where sufficient stock is available from an authorised source. Availability should be confirmed at quotation stage rather than assumed, as it depends on current stock in the supply chain for the specific product.

Is a CoA always available?

No. CoA (Certificate of Analysis) availability depends on the manufacturer, the market and the supply route for the specific product, and should be confirmed at quotation stage rather than assumed. Not every product or every batch comes with an available CoA.

How long does RLD/comparator sourcing from Europe take?

Lead time depends on the specific product, its current availability, the documentation required, and whether it is a controlled or scheduled product. Rather than quote a single figure, we assess and confirm lead time as part of each quotation.

Can ProPG source cold-chain or controlled products?

ProPG supports cold-chain sourcing as part of its GDP-aligned supply operations. Controlled and scheduled products are assessed on a case-by-case basis, taking into account the specific product, markets involved, and permits required — this should be flagged at the outset of a sourcing enquiry.